Skip to main content

Quest Extends HPV Marketing Deal With Digene for Four More Years

NEW YORK (GenomeWeb News) — Digene this week said it has extended by four years a three-year agreement with Quest Diagnostics under which Quest will market Digene’s test for human papillomavirus.
  
Digene will continue to supply Quest’s labs with the instrumentation and reagents for HPV testing, the company said.
 
Digene also said that Quest will “continue its efforts with Digene to educate and promote HPV screening along with the Pap test to its customer base of hospitals, physicians, and other healthcare providers.”

The test is used to detect HPV, which is “the recognized cause of cervical cancer,” and has been approved by the US Food and Drug Administration for use along with a Pap test in women aged 30 and older as a cervical cancer screen, Digene said.

 
Financial terms of the agreement were not released.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.